MGRXA small step, but in nuclear terms, that’s a big deal
Mangoceuticals’ merger partner, Nuclea Energy, just landed a memorandum of understanding with the Utah Office of Energy Development. The goal? Explore a test reactor site at the Utah San Rafael Energy Lab and keep nudging the Morpheus microreactor toward demonstration and eventual deployment.
Why investors are paying attention
This isn’t a commercial contract or a full buildout. It’s more like getting the keys to the gym before the championship game. Still, in the nuclear world, every regulatory, state, and site-selection handshake matters because these projects can stall for ages if the paperwork, politics, and safety review don’t line up.
For Mangoceuticals, the headline matters because its merger story is tied to Nuclea’s progress. If Nuclea keeps stacking these kind of milestones, it gives the deal more narrative fuel — and maybe a better chance of being seen as a real business plan instead of a press-release moonshot.
The big picture
The MOU also signals that Nuclea is trying to build relationships with the Utah site, the U.S. Department of Energy, and the Nuclear Regulatory Commission. Translation: they’re trying to clear the usual maze of approvals before anyone starts talking about shiny reactors and big promises.
Big picture: this is early, but it’s the kind of early that can matter in deep-tech investing. If the partnership keeps advancing, MGRX could get more attention as the merger story gains a tangible milestone.